| 期 |
栏目 |
标题 |
文件 |
| 卷 9, 编号 4 (2019) |
Articles |
Treatment with the first Russian direct-acting antiviral drug in patients with chronic hepatitis C |
|
| 卷 10, 编号 2 (2020) |
Articles |
Experience with narlaprevir in the treatment of chronic hepatitis C |
|
| 卷 10, 编号 4 (2020) |
Articles |
A modern view of the immunopathogenesis of chronic hepatitis B |
|
| 卷 12, 编号 1 (2022) |
Articles |
THE FEATURES OF THE COURSE OF HBV INFECTION DURING ANTIVIRAL THERAPY |
|
| 卷 12, 编号 2 (2022) |
Articles |
POST-COVID SYNDROME. PATHOGENESIS AND CLINICAL MANIFESTATIONS (PART 1) |
|
| 卷 12, 编号 2 (2022) |
Articles |
POSSIBILITIES FOR PREVENTION AND PATHOGENETIC THERAPY OF NOVEL CORONAVIRUS INFECTION |
|
| 卷 12, 编号 2 (2022) |
Articles |
EXPERIENCE WITH POPULIN WITH DIHYDROQUERCETIN IN NOVEL CORONAVIRUS INFECTION |
|
| 卷 13, 编号 1 (2023) |
Reviews and Lectures |
Chronic hepatitis C and its outcomes: liver cirrhosis, hepatocellular carcinoma |
|
| 卷 9, 编号 3 (2019) |
Articles |
New areas in therapy for chronic hepatitis B |
|
| 卷 13, 编号 2 (2023) |
Articles |
Viral hepatitis: yesterday, today, tomorrow |
|
| 卷 14, 编号 1 (2024) |
Exchange of Experience |
The effectiveness of the drug of direct antiviral action in children with chronic hepatitis C |
|
| 卷 14, 编号 4 (2024) |
Reviews and Lectures |
Biomarkers of liver fibrosis and cirrhosis in chronic hepatitis C. Clinical and pathophysiological aspects |
|
